Entergy reports Q3 2026 results with expected $1.72 EPS, driven by data-center and industrial load growth in its Gulf South territory.
Eli Lilly's ovarian cancer drug Sofe-M showed 79% confirmed response rate in phase 1 trials, but shares fell 2.5% despite the data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results